Sector News

Juan R. Luciano elected to Lilly board of directors

December 15, 2015
Life sciences

/PRNewswire/ – The board of directors of Eli Lilly and Company has elected Juan R. Luciano as a new member, effective February 1, 2016.

Luciano is chief executive officer and president of Archer Daniels Midland Company (ADM), and a member of the ADM board of directors.

“I am pleased to welcome Juan to the Lilly board,” said John C. Lechleiter, Ph.D., chairman, president and chief executive officer. “Juan brings to the Lilly board a global perspective and a proven track record of leading high-performance, results-focused organizations. We will benefit from Juan’s broad business experience, including his knowledge of the food and agriculture sectors.”

Luciano joined ADM in 2011 as executive vice president and chief operating officer. He was named president in February 2014, and in January 2015 became the ninth chief executive in ADM’s 112-year history.

Since joining ADM, Luciano has overseen the commercial and production activities of ADM’s Corn, Oilseeds and Agricultural Services businesses, as well as its research, project management, procurement and risk management functions. He led the company’s operational excellence initiatives, which seek to improve productivity and efficiency companywide, as well as the company’s efforts to improve its capital, cost and cash positions. Luciano also led the company’s move into ingredients.

Before joining ADM, Luciano had a successful 25-year tenure at The Dow Chemical Company, where he last served as executive vice president and president of the performance division.

Luciano is a governor of the Boys and Girls Clubs of America, and Midwest chair of the organization’s National Trustees Board. He holds an industrial engineering degree from the Buenos Aires Institute of Technology.

Source: Eli Lilly and Company

Related News

February 28, 2021

UCB taps Microsoft to accelerate drug discovery, clinical trials

Life sciences

The deal will see Microsoft use its capabilities in computational services, cloud computing and artificial intelligence to support drug discovery and development at UCB.

February 28, 2021

GSK to close two UK antibiotics manufacturing sites

Life sciences

The planned closures come as GSK has agreed to sell its cephalosporins antibiotics business to Sandoz, a division of Swiss pharma firm Novartis, for as much as US$500m.

February 28, 2021

Colorcon launches TiO2-free supplement coating

Life sciences

“The launch of these new formulations provides the nutritional market with much-needed alternative coating systems that address clean label consumer preferences and are easy to implement,” says Kelly Boyer, vice president film coatings at Colorcon.

Send this to a friend